877963-94-5
中文名稱
2-((4-(環(huán)丙烷羰基)哌嗪-1-基)甲基)苯并[D]異噻唑-3(2H)-酮
英文名稱
LOC-14
CAS
877963-94-5
分子式
C16H19N3O2S
分子量
317.41
MOL 文件
877963-94-5.mol
更新日期
2026/05/25 13:08:21
877963-94-5 結(jié)構(gòu)式
基本信息
中文別名
化合物L(fēng)OC142-((4-(環(huán)丙烷羰基)哌嗪-1-基)甲基)苯并[D]異噻唑-3(2H)-酮
2-[[[4-(環(huán)丙基羰基)-1-哌嗪基]甲基] -1,2-苯并異噻唑-3(2H) - 酮
英文別名
OC14LOC-14
LOC14, ≥98%
LOC 14
LOC14
LOC 14,inhibit,LOC14,Inhibitor,LOC-14
2-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]methyl]-1,2-benzisothiazol-3(2H)-one
2-((4-(cyclopropanecarbonyl)piperazin-1-yl)methyl)benzo[d]isothiazol-3(2H)-one
1,2-Benzisothiazol-3(2H)-one, 2-[[4-(cyclopropylcarbonyl)-1-piperazinyl]methyl]-
2-[(4-cyclopropanecarbonylpiperazin-1-yl)methyl]-2,3-dihydro-1,2-benzothiazol-3-one
物理化學(xué)性質(zhì)
沸點(diǎn)528.5±60.0 °C(Predicted)
密度1.390±0.06 g/cm3(Predicted)
儲(chǔ)存條件Sealed in dry,2-8°C
溶解度DMF: 10mg/mL; DMF:PBS (pH 7.2) (1:1): 0.5mg/mL; DMSO: 3mg/mL; Ethanol: 3mg/mL; Ethanol:PBS (pH 7.2) (1:6): 0.14mg/mL
酸度系數(shù)(pKa)6.16±0.10(Predicted)
形態(tài)結(jié)晶固體
顏色White to off-white
2-((4-(環(huán)丙烷羰基)哌嗪-1-基)甲基)苯并[D]異噻唑-3(2H)-酮價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-100432 | 2-((4-(環(huán)丙烷羰基)哌嗪-1-基)甲基)苯并[D]異噻唑-3(2H)-酮 LOC14 | 877963-94-5 | 1 mg | 360元 |
| 2026/06/05 | HY-100432 | 2-((4-(環(huán)丙烷羰基)哌嗪-1-基)甲基)苯并[D]異噻唑-3(2H)-酮 LOC14 | 877963-94-5 | 5mg | 1000元 |
| 2026/06/05 | HY-100432 | 2-((4-(環(huán)丙烷羰基)哌嗪-1-基)甲基)苯并[D]異噻唑-3(2H)-酮 LOC14 | 877963-94-5 | 10mg | 1688元 |
常見問題列表
生物活性
LOC14 是一種有效的 protein disulfide isomerase (PDI) 的抑制劑，EC50值為500 nM和Kd值為62 nM。靶點(diǎn)
Kd: 62 nM (PDI)
體外研究
LOC14 (0.01-100 μM; 24 hours) exhibits the capacity to inhibit recombinant (r)PDIA3 at an IC50 of approximately 5 μM.
Cell Viability Assay
| Cell Line: | MTEC cells |
| Concentration: | 0.01 μM; 0.1 μM; 0.5 μM; 1 μM; 5 μM; 10 μM; 100 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited recombinant (r)PDIA3 activity. |
體內(nèi)研究
LOC14 (orally administered by gavage; 20 mg/kg; once daily; 12-28 weeks) significantly improves motor function, attenuated brain atrophy and extended survival in the N171–82Q HD mice.
| Animal Model: | Male N171–82Q HD mice |
| Dosage: | 20 mg/kg |
| Administration: | Orally administered by gavage; 20 mg/kg; once daily; 12-28 weeks |
| Result: | Improved motor function in HD mice. |